Cantor Fitzgerald Forecasts Weaker Earnings for Precigen

Key Points

• Cantor Fitzgerald has revised its FY2026 EPS estimate for Precigen to $0.06 per share, down from the previous estimate of $0.07.
• Despite a negative net margin of 2,868.66%, Precigen reported revenue of $0.86 million for the last quarter, exceeding analyst expectations.
• Insider transactions included the sale of over 3.5 million shares by Director Randal J. Kirk, while CFO Harry Jr. Thomasian purchased 8,284 shares, reflecting differing confidence in the company's future.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2026 EPS estimates for Precigen in a report issued on Friday, September 26th. Cantor Fitzgerald analyst J. Kim now expects that the biotechnology company will post earnings of $0.06 per share for the year, down from their prior estimate of $0.07. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The company had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.67 million.

PGEN has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and set a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. JPMorgan Chase & Co. upgraded shares of Precigen from an "underweight" rating to a "neutral" rating in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. JMP Securities boosted their price target on shares of Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 19th. Finally, Citigroup reiterated an "outperform" rating on shares of Precigen in a research report on Tuesday, August 19th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Precigen presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.25.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $3.51 on Monday. Precigen has a 1 year low of $0.65 and a 1 year high of $5.22. The company's 50-day moving average is $3.11 and its 200 day moving average is $2.07. The stock has a market capitalization of $1.05 billion, a P/E ratio of -8.36 and a beta of 1.81.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PGEN. BNP Paribas Financial Markets bought a new position in shares of Precigen in the fourth quarter worth approximately $27,000. Apella Capital LLC bought a new position in shares of Precigen in the first quarter worth approximately $40,000. Voya Investment Management LLC lifted its stake in shares of Precigen by 142.9% in the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after buying an additional 21,633 shares in the last quarter. ProShare Advisors LLC lifted its position in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after purchasing an additional 10,900 shares during the period. Finally, Strs Ohio bought a new position in Precigen during the first quarter valued at approximately $70,000. Institutional investors own 33.51% of the company's stock.

Insider Buying and Selling

In other news, Director Randal J. Kirk sold 3,596,892 shares of the company's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $3.68, for a total value of $13,236,562.56. Following the transaction, the director owned 8,520,537 shares in the company, valued at approximately $31,355,576.16. This represents a 29.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Harry Jr. Thomasian bought 8,284 shares of the company's stock in a transaction dated Thursday, September 25th. The stock was purchased at an average price of $3.62 per share, for a total transaction of $29,988.08. Following the purchase, the chief financial officer owned 465,694 shares of the company's stock, valued at approximately $1,685,812.28. This represents a 1.81% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 52,221 shares of company stock valued at $207,667 over the last quarter. Corporate insiders own 47.10% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.